This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—The article by Tobin et al published in the January Archives (1982;100:81-83) on the safety of hydroxychloroquine sulfate recalls my experience with this drug in rheumatic diseases. During the past 15 years, I have followed up approximately 100 patients with rheumatoid arthritis and lupus erythematosus who were given hydroxychloroquine sulfate in doses of 200 to 400 mg/day. The average length of drug use was 36 months, with 12 patients using the drug up to eight years. In this whole group, no functional visual or anatomic ocular defects were noted on ocular examination.Since central vision tends to be most affected by this drug, it is my recommendation to use Amsler's charts, principally the red chart, to pick up the smallest and earliest central or paracentral defects.
Frenkel M. Safety of Hydroxychloroquine. Arch Ophthalmol. 1982;100(5):841. doi:10.1001/archopht.1982.01030030845024
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: